FlexPro MD®, a Combination of Krill Oil, Astaxanthin and Hyaluronic Acid, Reduces Pain Behavior and Inhibits Inflammatory Response in Monosodium Iodoacetate-Induced Osteoarthritis in Rats

被引:29
作者
Park, Min Hee [1 ]
Jung, Jae Chul [2 ]
Hill, Stephen [3 ]
Cartwright, Elizabeth [3 ]
Dohnalek, Margaret H. [3 ]
Yu, Min [4 ,5 ]
Jun, Hee Joon [4 ,5 ]
Han, Sang Bae [4 ,5 ]
Hong, Jin Tae [4 ,5 ]
Son, Dong Ju [4 ,5 ]
机构
[1] Ewha Womans Univ, Div Life & Pharmaceut Sci, 52 Ewhayeodae Gil, Seoul 03760, South Korea
[2] Novarex Co Ltd, R&D Ctr, 60 Gangni 1 Gil, Cheongju 28126, Chungbuk, South Korea
[3] US Nutraceut Inc dba Valensa Int, Eustis, FL 32726 USA
[4] Chungbuk Natl Univ, Coll Pharm, Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea
[5] Chungbuk Natl Univ, Med Res Ctr, Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea
基金
新加坡国家研究基金会;
关键词
FlexPro MD; krill oil; astaxanthin; hyaluronic acid; inflammation; pain; osteoarthritis; OLIGOMERIC MATRIX PROTEIN; ARTICULAR-CARTILAGE; II COLLAGEN; NUTRITIONAL INTERVENTIONS; KNEE OSTEOARTHRITIS; BIOCHEMICAL MARKERS; DISEASE PROGRESSION; CHONDROITIN SULFATE; PART I; MANAGEMENT;
D O I
10.3390/nu12040956
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Osteoarthritis (OA) is a degenerative joint disease and a leading cause of adult disability. Since there is no cure for OA and no effective treatment to slow its progression, current pharmacologic treatments, such as analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), only alleviate symptoms, such as pain and inflammation, but do not inhibit the disease process. Moreover, chronic intake of these drugs may result in severe adverse effects. For these reasons, patients have turned to the use of various complementary and alternative approaches, including diverse dietary supplements and nutraceuticals, in an effort to improve symptoms and manage or slow disease progression. The present study was conducted to evaluate the anti-osteoarthritic effects of FlexPro MD (R) (a mixture of krill oil, astaxanthin, and hyaluronic acid; FP-MD) in a rat model of OA induced by monosodium iodoacetate (MIA). FP-MD significantly ameliorated joint pain and decreased the severity of articular cartilage destruction in rats that received oral supplementation for 7 days prior to MIA administration and for 21 days thereafter. Furthermore, FP-MD treatment significantly reduced serum levels of the articular cartilage degeneration biomarkers cartilage oligomeric matrix protein (COMP) and crosslinked C-telopeptide of type II collagen (CTX-II), and the pro-inflammatory cytokines tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6), as well as mRNA expression levels of inflammatory mediators, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and matrix-degrading enzymes, matrix metalloproteinase (MMP)-2 and MMP-9, in the knee joint tissue. Our findings suggest that FP-MD is a promising dietary supplement for reducing pain, minimizing cartilage damage, and improving functional status in OA, without the disadvantages of previous dietary supplements and medicinal agents, including multiple adverse effects.
引用
收藏
页数:15
相关论文
共 68 条
[1]   Inflammation in osteoarthritis [J].
Goldring, Mary B. ;
Otero, Miguel .
CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (05) :471-478
[2]  
Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905
[3]   Do early life factors affect the development of knee osteoarthritis in later life: a narrative review [J].
Antony, Benny ;
Jones, Graeme ;
Jin, Xingzhong ;
Ding, Changhai .
ARTHRITIS RESEARCH & THERAPY, 2016, 18
[4]   Combined detection of serum CTX-II and COMP concentrations in osteoarthritis model rabbits: an effective technique for early diagnosis and estimation of disease severity [J].
Bai, Bin ;
Li, Yanqin .
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2016, 11
[5]  
Black C, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI [10.3310/htal3520, 10.3310/hta13520]
[6]   Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis [J].
Bove, SE ;
Calcaterra, SL ;
Brooker, RM ;
Huber, CM ;
Guzman, RE ;
Juneau, PL ;
Schrier, DJ ;
Kilgore, KS .
OSTEOARTHRITIS AND CARTILAGE, 2003, 11 (11) :821-830
[7]   Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) [J].
Bruyere, Olivier ;
Cooper, Cyrus ;
Al-Daghri, Nasser M. ;
Dennison, Elaine M. ;
Rizzoli, Rene ;
Reginster, Jean-Yves .
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 30 (02) :111-117
[8]   Nutraceutical Supplements in the Management and Prevention of Osteoarthritis [J].
Castrogiovanni, Paola ;
Trovato, Francesca Maria ;
Loreto, Carla ;
Nsir, Houda ;
Szychlinska, Marta Anna ;
Musumeci, Giuseppe .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (12)
[9]   Osteoarthritis: toward a comprehensive understanding of pathological mechanism [J].
Chen, Di ;
Shen, Jie ;
Zhao, Weiwei ;
Wang, Tingyu ;
Han, Lin ;
Hamilton, John L. ;
Im, Hee-Jeong .
BONE RESEARCH, 2017, 5
[10]   Use of NSAIDs in treating patients with arthritis [J].
Crofford, Leslie J. .
ARTHRITIS RESEARCH & THERAPY, 2013, 15